Ординатура / Офтальмология / Английские материалы / Anti-VEGF_Bandello, Parodi, Augustin_2010
.pdf
Anti-VEGF
Developments in Ophthalmology
Vol. 46
Series Editors
F. Bandello Milan
W. Behrens-Baumann Magdeburg
Anti-VEGF
Volume Editors
F. Bandello Milan
M. Battaglia Parodi Milan
Co-Editors
A.J. Augustin Karlsruhe
P. Iacono Rome
R.O. Schlingemann Amsterdam
U. Schmidt-Erfurth Vienna
F.D. Verbraak Amsterdam
12 figures, 5 in color, and 13 tables, 2010
Basel · Freiburg · Paris · London · New York · Bangalore ·
Bangkok · Shanghai · Singapore · Tokyo · Sydney
Francesco Bandello |
Maurizio Battaglia Parodi |
Department of Ophthalmology |
Department of Ophthalmology |
University Vita-Salute Scientific Institute |
University Vita-Salute Scientific Institute |
San Raffaele |
San Raffaele |
Via Olgettina, 60 |
Via Olgettina, 60 |
IT–20132 Milano (Italy) |
IT–20132 Milano (Italy) |
Library of Congress Cataloging-in-Publication Data
Anti-VEGF / volume editors, Francesco Bandello, M. Battaglia Parodi ; co-editors, A. Augustin ... [et al.].
p. ; cm. -- (Developments in ophthalmology, ISSN 0250-3751 ; v. 46) Includes bibliographical references and indexes.
ISBN 978-3-8055-9529-2 (hard cover : alk. paper) -- ISBN 978-3-8055-9530-8 (e-ISBN)
1. Eye--Blood-vessels--Diseases--Chemotherapy. 2. Vascular endothelial growth factors--Antagonists--Therapeutic use. I. Bandello, F. (Francesco) II. Battaglia Parodi, M. (Maurizio) III. Series: Developments in ophthalmology ; v. 46. 0250-3751
[DNLM: 1. Eye Diseases--therapy. 2. Vascular Endothelial Growth Factors--therapeutic use. 3. Neovascularization, Pathologic--therapy. W1 DE998NG v.46 2010 / WW 166 A6334 2010]
RE720.A58 2010 617.7 061--dc22
2010025184
Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents® and Index Medicus.
Disclaimer. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the book is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
© Copyright 2010 by S. Karger AG, P.O. Box, CH–4009 Basel (Switzerland) www.karger.com
Printed in Switzerland on acid-free and non-aging paper (ISO 9706) by Reinhardt Druck, Basel ISSN 0250–3751
ISBN 978–3–8055–9529-2 e-ISBN 978–3–8055–9530-8
Section Title
Contents
VII List of Contributors
IX Preface
Bandello, F. (Milan)
1Angiostatic and Angiogenic Factors
de Groot, H.; Schmit-Eilenberger, V.; Kirchhof, J.; Augustin, A.J. (Karlsruhe)
4Mechanisms of Ocular Angiogenesis and Its Molecular Mediators
Siemerink, M.J. (Amsterdam); Augustin, A.J. (Karlsruhe); Schlingemann, R.O. (Amsterdam)
21Antivascular Endothelial Growth Factors in Age-Related Macular Degeneration
Schmidt-Erfurth, U.; Pollreisz, A.; Mitsch, C.; Bolz, M. (Vienna)
39Antivascular Endothelial Growth Factor in Diabetic Retinopathy
Iacono, P. (Rome); Battaglia Parodi, M.; Bandello, F. (Milan)
54Retinal Vein Occlusions
Buehl, W.; Sacu, S.; Schmidt-Erfurth, U. (Vienna)
73Antivascular Endothelial Growth Factor for Choroidal Neovascularization in Pathologic Myopia
Battaglia Parodi, M. (Milan); Iacono, P. (Rome); Bandello, F. (Milan)
84Antivascular Endothelial Growth Factors for Inflammatory Chorioretinal Disorders
Battaglia Parodi, M. (Milan); Iacono, P. (Rome); Verbraak, F.D. (Amsterdam); Bandello, F. (Milan)
96Antivascular Endothelial Growth Factor Treatment in Pseudoxanthoma Elasticum Patients
Verbraak, F.D. (Amsterdam)
V
107Antivascular Endothelial Growth Factor in Hereditary Dystrophies
Battaglia Parodi, M. (Milan); Iacono, P. (Rome); Bandello, F. (Milan)
111Antivascular Endothelial Growth Factor as an Approach for Macular Edema
Buchholz, P.M.; Buchholz, A.P.; Augustin, A.J. (Karlsruhe)
123Angiogenesis and Vascular Endothelial Growth Factors in Intraocular Tumors
Missotten, G.S. (Leuven/Amsterdam); Schlingemann, R.O. (Amsterdam); Jager, M.J. (Leiden)
133Antivascular Endothelial Growth Factors in Anterior Segment Diseases
Scholl, S.; Kirchhof, J.; Augustin, A.J. (Karlsruhe)
140Author Index
141Subject Index
VI |
Contents |
List of Contributors
A.J. Augustin, Prof.
Augenklinik Moltkestrasse 90
DE–76133 Karlsruhe (Germany)
E-Mail albertjaugustin@googlemail.com
F. Bandello, Prof.
Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele
Via Olgettina, 60 IT–20132 Milano (Italy)
E-Mail bandello.francesco@hsr.it
M. Battaglia Parodi, Dr.
Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele
Via Olgettina, 60 IT–20132 Milano (Italy)
E-Mail battagliaparodi.maurizio@hsr.it
M. Bolz, Dr.
Department of Ophthalmology and Optometry
Medical University Vienna
Waehringer Guertel 18-20
AT–1090 Vienna (Austria)
E-Mail matthias.bolz@meduniwien.ac.at
A. Buchholz, Dr.
Augenklinik Moltkestrasse 90
DE–76133 Karlsruhe (Germany) E-Mail Andreas.Buchholz@ klinikum-karlsruhe.de
P. Buchholz, Dr.
Augenklinik Moltkestrasse 90
DE–76133 Karlsruhe (Germany) E-Mail apkbuchholz@yahoo.de
W. Buehl, Dr.
Department of Ophthalmology and Optometry
Medical University Vienna
Waehringer Guertel 18-20
AT–1090 Vienna (Austria)
E-Mail wolf.buehl@meduniwien.ac.at
H. de Groot, Dr.
Augenklinik Moltkestrasse 90
DE–76133 Karlsruhe (Germany) E-Mail developments@dr-de-groot.de
P. Iacono, Dr.
Fondazione G.B. Bietti per l’Oftalmologia IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico)
Via Livenza 3 IT–00198 Rome (Italy)
E-Mail pierluigi.iacono@libero.it
M.J. Jager, Prof.
Department of Ophthalmology LUMC
PO Box 9600
NL–2300 RC Leiden (The Netherlands) E-Mail m.j.jager@lumc.nl
VII
J. Kirchhof, Dr. |
U. Schmidt-Erfurth, Prof. |
|
Augenklinik |
Department of Ophthalmology and |
|
Moltkestrasse 90 |
Optometry |
|
DE–76133 Karlsruhe (Germany) |
Medical University Vienna |
|
E-Mail jannakirchhof@googlemail.com |
Waehringer Guertel 18-20 |
|
G.S. Missotten, Prof. |
AT–1090 Vienna (Austria) |
|
E-Mail ursula.schmidt-erfurth@ |
||
Department Ophthalmology |
meduniwien.ac.at |
|
Academic Medical Center |
V. Schmit-Eilenberger, Dr. |
|
Meibergdreef 9 |
||
NL–1100DD Amsterdam (The Netherlands) |
Augenklinik |
|
E-Mail guy.missotten@uzleuven.be |
Moltkestrasse 90 |
|
C. Mitsch, Dr. |
DE–76133 Karlsruhe (Germany) |
|
E-Mail dr.schmit-eilenberger@email.de |
||
Department of Ophthalmology and |
S. Scholl, Dr. |
|
Optometry |
||
Medical University Vienna |
Augenklinik |
|
Waehringer Guertel 18-20 |
Moltkestrasse 90 |
|
AT–1090 Vienna (Austria) |
DE–76133 Karlsruhe (Germany) |
|
E-Mail christoph.mitsch@meduniwien.ac.at |
E-Mail s-scholl@gmx.de |
|
A. Pollreisz, Dr. |
M.J. Siemerink, Dr. |
|
Department of Ophthalmology and |
Medical Retina Unit and Ocular |
|
Optometry |
Angiogenesis Group |
|
Medical University Vienna |
Department of Ophthalmology |
|
Waehringer Guertel 18-20 |
Academic Medical Center |
|
AT–1090 Vienna (Austria) |
University of Amsterdam, A2-122 |
|
E-Mail andreas.pollreisz@meduniwien.ac.at |
NL–1100 DD Amsterdam (The Netherlands) |
|
S. Sacu, Dr. |
E-Mail m.j.siemerink@amc.uva.nl |
|
F.D. Verbraak, Dr. |
||
Department of Ophthalmology and |
||
Optometry |
Departments of Ophthalmology and |
|
Medical University Vienna |
Biomedical Engineering & Physics |
|
Waehringer Guertel 18-20 |
Academic Medical Center |
|
AT–1090 Vienna (Austria) |
Meibergdreef 9 |
|
E-Mail stefan.sacu@meduniwien.ac.at |
NL–1105 AZ Amsterdam (The Netherlands) |
|
R.O. Schlingemann, Prof. |
E-Mail f.d.verbraak@amc.nl |
|
|
||
Medical Retina Unit and Ocular |
|
|
Angiogenesis Group |
|
|
Department of Ophthalmology |
|
|
Academic Medical Center |
|
|
University of Amsterdam, A2-122 |
|
|
NL–1100 DD Amsterdam (The Netherlands) |
|
|
E-Mail r.schlingemann@amc.uva.nl |
|
VIII |
List of Contributors |
Section Title
Preface
The development of vascular endothelial growth factor inhibitors for the treatment of ocular neovascularization and macular edema can be regarded as the beginning of a new era in ophthalmological therapy. Before the year 2000, the treatment of any vascular abnormality in the macular region was merely restricted to conventional laser photocoagulation. Indubitably, laser treatment represents a destructive procedure which leads to a permanent scar and brings about a retinal sensitivity deterioration in all cases. Since 2000, photodynamic therapy with verteporfin has been introduced as the first attempt to couple laser energy with a light-sensitive drug in an attempt to treat choroidal neovascularization through a relatively non-destructive form of therapy. Nevertheless, photodynamic therapy can provide only a very limited visual acuity improvement, especially in choroidal neovascularization secondary to age-related macular degeneration and pathologic myopia.
In an attempt to improve the functional outcomes, many researchers have studied the potential application of anti-angiogenic agents on ocular diseases. Previous investigations have demonstrated that vascular endothelial growth factor plays an important role in promoting angiogenesis and vascular leakage in several ocular pathologic conditions. The main goals of antivascular endothelial growth factor therapy are the inhibition of growth and development of new vessels, along with the reduction of vascular permeability.
The encouraging results of the most important randomized clinical trials regarding the efficacy of ranibizumab and pegaptanib on subfoveal choroidal neovascularization in relation to age-related macular degeneration have greatly influenced current medical practice. As a result, in the last few years, many applications have been proposed in an effort to treat several vascular diseases of the eye.
This aim of this book is to help update residents, general ophthalmologists, and retina specialists on the latest applications of antivascular endothelial growth factor
IX